In line with these findings, Heiblig et al. showed that in older AML patients IDH2 mutations seem to confer a more favourable outcome compared to IDH1 mutations (overall survival at three years 76% compared to 54%, respectively) [53]. Here, IDH2 is linked to acute myeloid leukemia.